A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood

Volumn 123, Issue 15, 2014, Pages 2308-2316

  McDermott, David H ^a   Liu, Qian ^a   Velez, Daniel ^a   Lopez, Lizbeeth ^a   Anaya O'Brien, Sandra ^a   Ulrick, Jean ^a   Kwatemaa, Nana ^a   Starling, Judy ^b   Fleisher, Thomas A ^b   Long Priel, Debra A ^c   Merideth, Melissa A ^d   Giuntoli, Robert L ^e   Evbuomwan, Moses O ^f   Littel, Patricia ^a   Marquesen, Martha M ^a   Hilligoss, Dianne ^a   DeCastro, Rosamma ^a   Grimes, George J ^b   Hwang, Samuel T ^g   Pittaluga, Stefania ^f   Calvo, Katherine R ^b   Stratton, Pamela ^h   Cowen, Edward W ^f   Kuhns, Douglas B ^c   Malech, Harry L ^a   Murphy, Philip M ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g MEDICAL COLLEGE OF WISCONSIN   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ELECTROLYTE; GRANULOCYTE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVER ENZYME; PLERIXAFOR; PNEUMOCOCCUS VACCINE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BONE PAIN; BRONCHIECTASIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONDYLOMA ACUMINATUM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ELECTROCARDIOGRAM; ELECTROLYTE BLOOD LEVEL; ENZYME BLOOD LEVEL; FAINTNESS; FEMALE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMATOCRIT; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE REACTION; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIMIT OF DETECTION; LONG TERM CARE; LOW DRUG DOSE; MALE; MEMORY CELL; MEMORY T LYMPHOCYTE; MIDDLE AGED; MONOCYTE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SELF INJECTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; WHIM SYNDROME;

ADULT; FEMALE; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MIDDLE AGED; RECEPTORS, CXCR4; TIME FACTORS; WARTS;

EID: 84899064355     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527226     Document Type: Article

References (36)

1. Zuelzer WW. "Myelokathexis"-a New Form of Chronic Granulocytopenia. Report of a Case. N Engl J Med. 1964;270:699-704.
2. Krill CE Jr, Smith HD, Mauer AM. Chronic Idiopathic Granulocytopenia. N Engl J Med. 1964;270:973-979.
3. Wetzler M, Talpaz M, Kleinerman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med. 1990;89(5):663-672. (Pubitemid 20384326)
4. Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol. 2009;16(1):20-26.
5. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet. 2003;34(1):70-74. (Pubitemid 36548793)
6. McDermott DH, Lopez J, Deng F, et al. AMD3100 is a potent antagonist at CXCR4(R334X), a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med. 2011;15(10):2071-2081.
7. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449-2457. (Pubitemid 40387045)
8. McCormick PJ, Segarra M, Gasperini P, Gulino AV, Tosato G. Impaired recruitment of Grk6 and beta-Arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 mutant receptor. PLoS ONE. 2009;4(12):e8102.
9. Kawai T, Choi U, Cardwell L, et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood. 2007;109(1):78-84. (Pubitemid 46070121)
10. Walters KB, Green JM, Surfus JC, Yoo SK, Huttenlocher A. Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. Blood. 2010;116(15):2803-2811.
11. Balabanian K, Brotin E, Biajoux V, et al. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood. 2012;119(24):5722-5730.
12. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81(10):2496-2502. (Pubitemid 23147550)
13. Favre O, Leimgruber A, Nicole A, Spertini F. Intravenous immunoglobulin replacement prevents severe and lower respiratory tract infections, but not upper respiratory tract and non-respiratory infections in common variable immune deficiency. Allergy. 2005;60(3):385-390. (Pubitemid 40293358)
14. Beaussant Cohen S, Fenneteau O, Plouvier E, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71.
15. DiPersio JF, Micallef IN, Stiff PJ, et al; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
16. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010;45(1):39-47.
17. Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood. 2011;118(18):4963-4966.
18. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood. 2011;118(18):4957-4962.
19. Ma Q, Jones D, Borghesani PR, et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci USA. 1998;95(16):9448-9453. (Pubitemid 28506251)
20. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393(6685):591-594. (Pubitemid 28319250)
21. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393(6685):595-599. (Pubitemid 28319251)
22. Hendrix CW, Collier AC, Lederman MM, et al; AMD3100 HIV Study Group. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr. 2004;37(2):1253-1262. (Pubitemid 39281506)
23. Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother. 2000;44(6):1667-1673. (Pubitemid 30340812)
24. Hübel K, Liles WC, Broxmeyer HE, et al. Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. Support Cancer Ther. 2004;1(3):165-172.
25. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307-1318. (Pubitemid 40629073)
26. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8):2728-2730. (Pubitemid 37248839)
27. Domanska UM, Kruizinga RC, Nagengast WB, et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 2013;49(1):219-230.
28. Gulino AV, Moratto D, Sozzani S, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood. 2004;104(2):444-452. (Pubitemid 38900027)
29. Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R, Easterbrook PJ. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS ONE. 2012;7(11):e40623.
30. Mc Guire PJ, Cunningham-Rundles C, Ochs H, Diaz GA. Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome. Clin Immunol. 2010;135(3):412-421.
31. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004;5(9):943-952. (Pubitemid 39276239)
32. Tokoyoda K, Zehentmeier S, Hegazy AN, et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity. 2009;30(5):721-730.
33. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol. 2005;174(3):1269-1273.
34. Herndler-Brandstetter D, Landgraf K, Jenewein B, et al. Human bone marrow hosts polyfunctional memory CD4+ and CD8+ T cells with close contact to IL-15-producing cells. J Immunol. 2011;186(12):6965-6971.
35. Chow KY, Brotin E, Ben Khalifa Y, et al. A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome. Cell Host Microbe. 2010;8(6):523-533.
36. Tassone L, Moratto D, Vermi W, et al. Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients. Blood. 2010;116(23):4870-4873.